ImmunoPET and biodistribution with human epidermal growth factor receptor 3 targeting antibody89Zr-RG7116

RG7116, a Therapeutic Antibody That Binds the Inactive HER3 Receptor and Is Optimized for Immune Effector Activation

(2013) C. Mirschberger et al.   CANCER RESEARCH

Inhibiting HER3-Mediated Tumor Cell Growth with Affibody Molecules Engineered to Low Picomolar Affinity by Position-Directed Error-Prone PCR-Like Diversification

(2013) Magdalena Malm et al.   PLoS One

Pertuzumab: new hope for patients with HER2-positive breast cancer

(2012) M. Capelan et al.   ANNALS OF ONCOLOGY

GA201 (RG7160): A Novel, Humanized, Glycoengineered Anti-EGFR Antibody with Enhanced ADCC and Superior In Vivo Efficacy Compared with Cetuximab

(2012) C. A. Gerdes et al.   CLINICAL CANCER RESEARCH

Resistance to HER2-directed antibodies and tyrosine kinase inhibitors

(2011) Joan T. Garrett et al.   CANCER BIOLOGY & THERAPY

Phase I Pharmacokinetic and Pharmacodynamic Dose-Escalation Study of RG7160 (GA201), the First Glycoengineered Monoclonal Antibody Against the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors

(2011) Luis G. Paz-Ares et al.   JOURNAL OF CLINICAL ONCOLOGY

Anti-HER agents in gastric cancer: from bench to bedside

(2011) Lorenzo Fornaro et al.   Nature Reviews Gastroenterology & Hepatology

Evaluation of 111In labeled antibodies for SPECT imaging of mesothelin expressing tumors

(2011) Ripen Misri et al.   NUCLEAR MEDICINE AND BIOLOGY

Immuno-Positron Emission Tomography: Shedding Light on Clinical Antibody Therapy

(2010) Guus A.M.S. van Dongen et al.   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

HER3 Comes of Age: New Insights into Its Functions and Role in Signaling, Tumor Biology, and Cancer Therapy

(2010) M. R. Campbell et al.   CLINICAL CANCER RESEARCH

Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer

(2010) E C Dijkers et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Understanding resistance to EGFR inhibitors—impact on future treatment strategies

(2010) Deric L. Wheeler et al.   Nature Reviews Clinical Oncology

The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics

(2010) Dhara N. Amin et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

Trastuzumab-Induced HER Reprogramming in "Resistant" Breast Carcinoma Cells

(2009) M. Narayan et al.   CANCER RESEARCH

PET of EGFR Antibody Distribution in Head and Neck Squamous Cell Carcinoma Models

(2009) G. Niu et al.   JOURNAL OF NUCLEAR MEDICINE

Development and Characterization of Clinical-Grade 89Zr-Trastuzumab for HER2/neu ImmunoPET Imaging

(2009) E. C.F. Dijkers et al.   JOURNAL OF NUCLEAR MEDICINE

Receptor-Binding, Biodistribution, and Metabolism Studies of 64Cu-DOTA-Cetuximab, a PET-Imaging Agent for Epidermal Growth-Factor Receptor-Positive Tumors

(2008) Wen Ping Li et al.   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840

(2008) Andrew D. Seidman et al.   JOURNAL OF CLINICAL ONCOLOGY

Disparity Between In Vivo EGFR Expression and 89Zr-Labeled Cetuximab Uptake Assessed with PET

(2008) H. J.W.L. Aerts et al.   JOURNAL OF NUCLEAR MEDICINE